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Purpose: Given the importance of understanding the genetic variations involved in the pathogen-
esis of non-Hodgkin’s lymphoma (NHL), this work was designed to study the impact of IL-10
(1082 G/A; rs1800896 and 819 C/T; rs1800871) gene promoter polymorphism on susceptibility
of Egyptians to diffuse large B cell lymphoma (DLBCL); the major type of NHL. To the best of our
knowledge, this study is the ﬁrst one that examines IL-10 promoter polymorphism in DLBCL in
Egyptians.
Methods: Genotyping polymorphism is performed using sequence-speciﬁc primers polymerase
chain reaction (SSP-PCR) in 100 Egyptian DLBCL patients and 119 normal controls. Circulating
plasma levels of IL-10 were measured using Enzyme-linked immunosorbent assay (ELISA).
Results: Insigniﬁcant change in IL-10 (1082 and 819) genotypes was recorded. Although A
allele is slightly decreased in DLBCL patients, it did not reach statistical signiﬁcance. GT haplotype
was signiﬁcantly elevated (P< 0.05) in NHL patients. A signiﬁcant linkage disequilibrium between
the 1082 and 819 SNPs with D0 = 0.596 and r2 = 0.1032 (P< 0.001) was demonstrated.
Signiﬁcantly increased plasma IL-10 (P< 0.01) was found which is positively correlated
(r= 0.307; P< 0.01) with the disease.00219001; fax: +20 48 260
m (R.M. Talaat).
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8 R.M. Talaat et al.Conclusions: Taken together, our ﬁndings demonstrated that IL-10 promoter gene polymor-
phism (1082 and 819) may not have an inﬂuence on the clinical outcome of DLBCL, especially
in terms of overall secretion level. Further investigations of other cytokine gene polymorphisms will
lead to a better understanding of the disease’s biological background.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Non-Hodgkin’s lymphoma is a heterogeneous group of hema-
tological malignancies [1,2]. It represents the sixth most com-
mon cause of cancer death worldwide [2]. Approximately
287,000 new cases of NHL are reported in the world each year
[3]. Several subtypes of NHL were characterized. The two ma-
jor subtypes are diffuse large B-cell lymphoma (DLBCL) and
follicular lymphoma (FL) [4]. Diffuse large B cell lymphoma
(DLBCL) accounts for approximately one third of all adult
NHL cases [5]. The interaction of the host immune response
with NHL and the impact of this interaction on the clinical
outcome of the disease are not yet fully understood.
Many cytokines are known to be involved in the pathogen-
esis of NHLs [6]. Recent studies suggested that several cyto-
kine gene polymorphisms were associated with susceptibility
to NHL [7] including interleukin-10 which acts as a growth
factor for normal activated human B and T lymphocyte stim-
ulation and proliferation [4,8,9]. IL-10 has been found to act as
an autocrine growth factor which up-regulates apoptosis regu-
lator Bcl-2 expression in some B-cell malignancies [10,11].
Some evidences suggest that IL-10 might be associated with
the progression of T-cell NHLs and in the pathogenesis of
DLBCL as IL-10 may be involved in a rescue effect, protecting
T cells from apoptotic cell death associated with up regulated
bcl-2 expression [12].
The gene encoding IL-10 is located on chromosome 1
(1q31–1q32) [13,14]. It has been reported that 3 SNPs in the
IL-10 gene promoter, including (1082, 819, and 592)
may inﬂuence IL-10 production in vitro [15]. Studies of Skibo-
la et al. [4] and Kube et al. [16] suggested that IL-10 gene poly-
morphisms were associated with susceptibility to NHL.
Recently, a meta-analysis of Cao et al. [17] suggested that
IL-10 3575 A allele confers a greater risk to DLBCL suscep-
tibility, while 1082 A/G polymorphism may have a signiﬁ-
cant association with DLBCL risk. However, no such study
was performed on Egyptian population. Thus, this study was
conducted to investigate the genotype distribution of IL-10
(1082 G/A; rs1800896 and 819 C/T; rs1800871) in DLBCL
Egyptian patients in view of its potential contribution to the
pathogenesis of the disease. Plasma level of IL-10 was mea-
sured in the same patients and control groups to determine
whether the change in the level of these cytokines is associated
or independent of the genetic markers at these polymorphic
sites.
2. Subjects and methods
2.1. Patients and controls
This study was conducted on 100 DLBCL patients (58 men
and 42 women; mean age 50.32 ± 14.58 years; range 17–
79 years) recruited consecutively from the Oncology Hospital,Menuﬁa University (Shebein El-kom, Menuﬁa Governorate,
Egypt). One hundred nineteen unrelated healthy blood donors
free of any chronic diseases, living in the same geographical
area and having the same ethnic origin as patients were re-
cruited as normal healthy controls. Informed consent was ob-
tained from all the study subjects. All investigations were done
in accordance with the Menuﬁa University, Health and Hu-
man Ethical Clearance Committee guidelines for Clinical Re-
searches. Local ethics committee approved the study protocol.
Cases were categorized according to the WHO classiﬁcation
[1] and the diagnosis of NHL was conﬁrmed by histology and
immunohistochemistry tests. The initial medical evaluation
consisted of a complete history and physical examination;
chest radiographic examination; computed tomographic scan
of the chest, abdomen, and pelvis; blood chemistry and bone
marrow biopsy or aspirate was performed at diagnosis. The ex-
tent of the disease was categorized according to the Ann Arbor
classiﬁcation and performance status was assessed using crite-
ria of the Eastern Cooperative Oncology Group (ECOG) [18].
2.2. DNA isolation
Blood samples were collected on ethylene-diamine-tetra-acetic
acid (EDTA) tube by venipuncture from all subjects. Genomic
DNA was extracted from whole blood-EDTA samples using
Wizard Genomic DNA Puriﬁcation Kit (Promega Co., WI,
USA) according to the manufacturer’s instructions.
2.3. Genotyping
IL-10 (1082 G/A and 819 C/T) SNPs were analyzed by se-
quence-speciﬁc primers polymerase chain reaction (SSP-PCR)
as an ARMS-PCR (ampliﬁcation mutation (refractory sys-
tem.) using four primer mixtures [19]. For 1082 G/A, primer
G (sense): 5’’-CTACTAAGGCTTCTTTGGGAG-30 primer;
A (sense): 5’’-ACTACTAAGGCTTCTTTGGGAA-30 and
antisense: primer (antisense): 5’’-CAG-
TGCCAACTGAGAATTTGG-30 were used. For 819 C/T,
primer C (sense): 50-CCCTTGTACAGGTGATGTAAC-30;
primer T (sense): 50-ACCCTTGTACAGGTGATGTAAT-30
and antisense: primer (antisense): 50-AGGATGTGTTC-
CAGGCTCCT-30 were used. As internal control the following
primers sense: 50-GCCTTCCCAACCATTCECTTA-3’’ and
antisense: 50-TCACGGATTTCTGTTGTGTTTC-30 were
used. The reaction was done in two tubes one for each allele,
the ﬁnal volume for each PCR reaction was 25 ll. The PCR
mixtures consisted of DreamTaq Green PCR Master Mix
(2·) (Fermentas, Thermo Fisher Scientiﬁc Inc.), 10 pmol of
each allele-speciﬁc primer, 10 pmol of antisense primer,
3.5 pmol of each control primer and 100 ng of DNA. PCR cy-
cling conditions consisted of 94 C for 2 min [1 cycle], followed
by 96 C for 25 s, 70 C for 45 s, and 72 C for 20 s [5 cycles];
followed by 96 C for 25 s, 65 C for 50 s, and 72 C for 45 s
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Figure 1b IL-10 (819 C/T) PCR products of three samples.
Lane (1) 100 bp ladder, Sample 1 in lane (2 and 3) CT genotype,
sample 2 in lane (4and 5) CC genotype and sample 3 in lane (6 and
7) TT genotype.
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for 2 min [15 cycles]. The control primer resulted in amplicon
of 429 bp and the 1082 primers resulted in an amplicon of
258 bp while the 819 primers resulted in an amplicon of
233 bp. By 2% agarose gel, the size of PCR products was
determined relatively to the migration of a 100 bp step ladder
(Fermentas) (Figs. 1a and 1b).
2.4. Measurement of plasma IL-10 by enzyme-linked
immunosorbent assay (ELISA)
Blood samples were collected from all patients and controls,
plasma separated by centrifugation at 1500 rpm for 15 min
at 4 C, aliquotted, and stored at 80 C until cytokine analy-
sis. Total concentrations of IL-10 in blood samples were mea-
sured using a commercial ELISA kit (R&D System, Inc.,
Minneapolis, MN), according to the manufacturer’s instruc-
tions. The intensity of the developed color was measured by
reading optical absorbance at 450 nm using a microplate read-
er (SunriseTM, Tecan Group Ltd. Ma¨nnedorf, Switzerland)).
The ELISA reader-controlling software (Softmax) processed
the digital data of raw absorbance values into a standard
curve, from which the IL-10 concentration of the samples
was derived. Results were expressed as pictogram of cytokine
per milliliter plasma (pg/ml).
2.5. Statistical analysis
All statistical analyses were performed using the Statistical
Package for Social Science (SPSS) version 13 (LEAD Technol-
ogy Inc.). Analysis of SNPs was done according to the factors
of the international prognostic index [IPI; age [IPI] >60 years,
lactate dehydrogenase (LDH) > N, Eastern Cooperative
Oncology Group (ECOG) > 1, stage III/IV > 1 extranodal
involvement to be representative for the disease population].
Data were presented as means with corresponding standard
deviation (SD). Comparisons among different groups were
performed by independent T-test. Chi-square test was used
to compare the frequency of variables in different groups,
and OR and 95% CI were calculated as determined by the pro-
gram software. Correlation between variables was determined
using Sperman’s correlation test. P value that remained below
0.05 after correction for the number of variables (P corrected,
Pc) was considered signiﬁcant (Bonferroni correction). The400 bp
100 bp 
258 bp429 bp
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Figure 1a IL-10 (1082 G/A) PCR products of seven samples.
Lane (1) 100 bp ladder, sample 1 in lane (2 and 3), sample 2 in lane
(4 and 5), sample 3 in lane (6 and 7) and sample 4 in lane (8 and 9)
are GA genotype, sample 5 in lane (10 and 11) and sample 6 in
lane (12 and 13) are AA genotype and sample 7 in lane (14 and 15)
GG genotype.haplotype frequencies were estimated with linkage disequilib-
rium coefﬁcient, D, using SNPSTAT program (available at
http://bioinfo.iconcologia.net/snpstats /start.htm). D was ex-
pressed as D0 giving the value of D as a percentage of the max-
imum calculated value given the observed allele frequencies.
Values of D0 ranged between 1 and +1. A/D0/value of 1 de-
noted complete linkage disequilibrium whereas a value of 0 de-
noted complete linkage equilibrium.
3. Results
3.1. Patient’s characteristics
The detailed biochemical characteristics of the patients en-
rolled in this study are presented in Table 1.
3.2. Association between IL-10 polymorphisms and NHL
Two pictures of gel electrophoresis of different genotypes of
IL-10 are shown in Figs. 1a and 1b. The IL-10 (1082 G/A
and 819 C/T) genotypes and allele frequencies in patients
and healthy controls are shown in Table 2. Analysis of SNPs
revealed that, there was an insigniﬁcant change in the distribu-
tion of IL-10 (1082 G/A and 819 C/T) genotypes between
patients and healthy controls. Although A allele is slightly de-
creased in DLBCL patients, it did not reach statistical
signiﬁcance.
The frequency of IL-10 (1082/819) haplotypes in
DLBCL patients and healthy controls is shown in Table 3.
The AC was the most frequent haplotype in controls and the
GC in patients. The GT is the lower one in both groups. There
was a signiﬁcant increase in GT haplotype in DLBCL patients
(P< 0.05) compared to controls. The linkage disequilibrium
(LD) pattern between the 1082 G/A and 819 C/T SNP
showed a signiﬁcant (P< 0.001) LD, with a D0 value of
0.596 and an r2 (the coefﬁcient of determination) value of
0.1032.
3.3. Plasma levels of IL-10 in NHL patients
A signiﬁcant increase (P< 0.01) in IL-10 in DLBCL patients
compared to healthy controls (56411.08 ± 11802.60 versus
5053.32 ± 279.64) was demonstrated. The disease was signiﬁ-
cantly correlated with elevation of IL-10 (r= 0.307; P< 0.01)
secretion level.
Table 3 Haplotype frequencies of the IL-10 (1082 and 819) polymorphisms in control and Diffuse large B-cell lymphoma
(DLBCL) patients.
Haplotype Control group (N= 119) DLBCL group (N= 100) % p OR (95% CI)
GC 36.68 36.54 NS 1.00
AC 37.27 30.46 NS 0.82 (0.50–1.35)
AT 24.50 24.54 NS 1.03 (0.59–1.80)
GT 1.55 8.46 p< 0.05* 6.46 (1.26–33.13)
p< 0.01.
p p< 0.001.
P: p-Value (signiﬁcant), Pc: P corrected, p/pc: gives Bonferroni correction, NS: not signiﬁcant.
* Correlation coefﬁcients in bold are statistically signiﬁcant with p< 0.05.
Table 1 Biochemical characteristics of control and diffuse large B-cell lymphoma (DLBCL) patients.
Laboratory investigations Control group (N= 119)
(Mean ± SD)
DLBCL group (N= 100)
(Mean ± SD)
p
WBCs (1000/mm3) 6.58 ± 2.03 8.53 ± 6.29 p< 0.01*
Hemoglobin (mmol/L) 8.32 ± 1.0 6.55 ± 1.31 p< 0.001**
PLT (1000/mm3) 267.59 ± 63.04 285.72 ± 166.21 NS
AST (IU/L) 21.96 ± 5.85 49.61 ± 43.51 p< 0.001**
ALT (IU/L) 17.91 ± 5.05 45.81 ± 50.09 p< 0.001**
ALB (lmol/L) 623.82 ± 57.09 527.19 ± 80.12 p< 0.001**
Bilirubin (lmol/L) 11.80 ± 3.57 21.92 ± 42.88 p< 0.01*
Creatinine (lmol/L) 76.71 ± 13.69 118.65 ± 107.76 p< 0.01*
LDH (IU/L) 326.61 ± 43.27 548.78 ± 477.67 p< 0.001**
All data are presented as mean ± SD. Platelet (PLT), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Albumin (ALB),
Lactate dehydrogenase (LDH).
Correlation coefﬁcients in bold are statistically signiﬁcant with p< 0.05.
NS: not signiﬁcant.
* p< 0.01.
** p p< 0.001.
Table 2 Genotype distribution and allelic frequency of the IL-10 (1082 G/A and 819 T/C) in controls and patients with Diffuse
large B-cell Lymphoma (DLBCL).
Cytokine gene Control group N= 119) DLBCL group (N= 100) p/pc OR (95% CI)
IL-10 (1082 G/A) Genotype (N, %)
G/G 15 (12.6%) 18 (18.0%) NS 1.522 (0.723–3.202)
G/A 61 (51.3%) 54 (54.0%) NS 1.116 (0.655–1.902)
A/A 43 (36.1%) 28 (28.0%) NS 0.687 (0.387–1.221)
GAAA 104 (87.4%) 82 (82.0%) NS 0.657 (0.312–1.382)
Allele frequency
G 91 (38.0%) 90 (45.0%) NS 1.321 (0.902–1.933)
A 147 (62.0%) 110 (55.0%) NS 0.756 (0.516–1.108)
IL-10 (819 C/T) Genotype (N, %)
C/C 62 (52.1%) 40 (40.0%) NS 0.613 (0.358–1.050)
C/T 52 (43.7%) 54 (54.0%) NS 1.513 (0.886–2.582)
T/T 5 (4.2%) 6 (6.0%) NS 1.455 (0.431–4.919)
CTTT 57 (47.9%) 60 (60.0%) NS 1.632 (0.953–2.794)
Allele frequency
C 176 (74.0%) 134 (67.0%) NS 0.715 (0.473–1.081)
T 62 (26.0%) 66 (33.0%) NS 1.398 (0.925–2.113)
P: p-Value (signiﬁcant), Pc: P corrected, p/pc: gives Bonferroni correction, NS: not signiﬁcant.
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according to polymorphisms
As shown in Table 4, the mean plasma concentration of IL-10
(1082 G/A) was increased signiﬁcantly (P< 0.01/Pc< 0.01,
P< 0.01/Pc< 0.01 and P< 0.001/Pc< 0.001) in DLBCL
patients with GG, GA and AA genotypes; respectively. The
same results were observed in IL-10 (819 C/T) where IL-10
was elevated in patients with CC and CT (P< 0.01/
Pc< 0.01 and P< 0.001/Pc< 0.001, respectively).
4. Discussion
Polymorphisms in genes coding for molecules critical in the
disease development and progression are likely to represent
key factors in the ampliﬁcation of intrinsic biological differ-
ences, resulting in clinically distinct outcomes [20]. IL-10 is a
multifunctional cytokine; it can stimulate proliferation and dif-
ferentiation of tumor B cells [21] and play an important role in
the malignant lymphoma development process [9]. It has been
reported that IL-10 SNPs may inﬂuence immune function
through modulating the activities of NK, T cells and macro-
phages and thus alter the disease progression [22]. Our results
showed that allelic frequencies and genotypic distributions at
the IL-10 (819) polymorphisms did not differ between
DLBCL patients and the control group. These data are consis-
tent with those previously reported by Lech-Maranda et al.
[18] and Purdue et al. [23]. The same result was found in-L-
10 (1082) which is consistent with those presented by Ghiel-
mini and Mora [24] where the frequency of the IL-10 (1082)
G allele was not signiﬁcantly different in DLBCL patients ver-
sus the control group. In contrast, a contradictory result was
obtained by Purdue et al. [23]. Carriers of the IL-10 (1082)
G allele are increased in NHL patients compared with healthy
controls and this was in agreement with Lech-Maranda et al.
[18] in DLBCL. A recent study suggested that 1082 G/A
was no longer statistically signiﬁcant among Hispanic whites
[25]. It is obvious that the investigation on the relationship be-
tween IL-10 SNPs and DLBCL was not always consistent.
Some studies have found correlations between 1082 A/GTable 4 Mean serum concentrations of interleukin IL-10 according
Diffuse large B-cell lymphoma (DLBCL) patients.
Genotype Control group
(N= 119)
(Mean ± SE)
IL-10 (1082 G/A) (pg/ml) (N)
G/G (15, 18) 5593.6 ± 1193.8
G/A (61, 54) 4966.3 ± 340.0
A/A (43, 28) 5021.3 ± 498.2
IL-10 (819 C/T) (pg/ml) (N)
C/C (62, 40) 5087.2 ± 413.7
C/T (52, 54) 5187.0 ± 397.2
T/T (5, 6) 3242.0 ± 862.7
Correlation coefﬁcients in bold are statistically signiﬁcant with p< 0.05.
* p< 0.01.
** p p< 0.001.and the risk of DLBCL [7,23,26]. However, other groups have
failed to conﬁrm these associations [27,28]. This stressed the
fact that different ethnic groups have different panels of poly-
morphisms in certain gene.
In our study, serum IL-10 concentration was signiﬁcantly
higher in patients compared to the healthy controls. Our re-
sults were consistent with previously documented data [9,29–
31]. Increased serum levels of IL-10 reﬂect an enhanced activa-
tion of the immune system on more aggressive disease, but its
potential action as a growth factor for lymphoma cells or as a
suppressor of macrophages or T-cell functions should also be
taken into account [32]. The increase of IL-10 production with-
in tumor microenvironment might be protective and con-
versely, that low IL-10 producing capability makes
individuals susceptible to more aggressive course of the disease
[33,34]. Increased serum levels of IL-10 were found in DLBCL
patients and were correlated with adverse disease features and
poor DLBCL outcome [35,36]. Although IL-10 gene promoter
polymorphisms might affect the levels of IL-10 expression [15],
in our work, the increase in IL-10 production levels in lym-
phoma patients is independent on the genotype of the patient
either in IL-10 (1082) or IL-10 (819) loci. Our result was
consistent with the result obtained from Lech-Maranda et al.
[18]. Few studies have linked polymorphism with secretion le-
vel, with a lot of inconsistence data. This arise the importance
of evaluating the real effect of IL-10 promotor gene polymor-
phism on IL-10 secretion level in different ethnic origins of sev-
eral populations.5. Conclusions
In conclusion, this preliminary data indicated that IL-10
(1082 and 819) genotypes did not play a role in DLBCL
susceptibility in Egyptian patients. The variation documented
in this work from other studies in different populations could
be returned to the ethnic differences. Therefore, larger pro-
spective studies are needed to conﬁrm our ﬁndings. In the light
of these data, further studies concerning other cytokine gene
polymorphisms will contribute to a better understanding of
the pathogenesis of the disease.to gene polymorphism (1082 G/A, 819 C/T) in controls and
DLBCL group
(N= 100)
(Mean ± SE)
p/pc
50732.7 ± 11967.3 p< 0.01/pc< 0.01*
74433.6 ± 21042.5 p< 0.01/pc< 0.01*
25303.5 ± 5489.5 p< 0.001/pc< 0.001**
57227.7 ± 21035.6 p< 0.01/pc< 0.01*
61648.1 ± 15307.7 p< 0.001/pc< 0.001**
3833.3 ± 1275.8 NS
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